Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "First-in-Human Phase 1/2a Study of the First-in-Class, Next-Generation CDK4-Selective Inhibitor PF-07220060 in Combination With ET in Patients With HR+/HER2- mBC"
By
Insights from ESMO Breast 2024 Annual Meeting
FEATURING
Timothy Yap
By
Insights from ESMO Breast 2024 Annual Meeting
FEATURING
Timothy Yap
Login to view comments.
Click here to Login
